NCT01583647

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 10 Years – 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial hypercholesterolemia.

Conditions

• Hypercholesterolemia, Familial
• Heterozygous Familial Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	MK-0524A	1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
DRUG	MK-0524A	2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally

Timeline

• Start date: 2012-06-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2012-04-24
• Last updated: 2015-11-03
• Results posted: 2013-12-04